ABVX vs. ZNTL, OPK, OCUL, SAVA, ETNB, MGNX, PRAX, ARQT, IMNM, and SPRY
Should you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Zentalis Pharmaceuticals (ZNTL), OPKO Health (OPK), Ocular Therapeutix (OCUL), Cassava Sciences (SAVA), 89bio (ETNB), MacroGenics (MGNX), Praxis Precision Medicines (PRAX), Arcutis Biotherapeutics (ARQT), Immunome (IMNM), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical preparations" industry.
ABIVAX Société Anonyme (NASDAQ:ABVX) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, community ranking, media sentiment, dividends, institutional ownership, valuation and profitability.
47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. 6.1% of Zentalis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
ABIVAX Société Anonyme's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.
Zentalis Pharmaceuticals received 48 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 66.67% of users gave ABIVAX Société Anonyme an outperform vote while only 65.00% of users gave Zentalis Pharmaceuticals an outperform vote.
In the previous week, Zentalis Pharmaceuticals had 21 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 25 mentions for Zentalis Pharmaceuticals and 4 mentions for ABIVAX Société Anonyme. ABIVAX Société Anonyme's average media sentiment score of 1.66 beat Zentalis Pharmaceuticals' score of 0.44 indicating that ABIVAX Société Anonyme is being referred to more favorably in the media.
ABIVAX Société Anonyme currently has a consensus price target of $32.00, suggesting a potential upside of 129.39%. Zentalis Pharmaceuticals has a consensus price target of $37.14, suggesting a potential upside of 210.17%. Given Zentalis Pharmaceuticals' higher possible upside, analysts plainly believe Zentalis Pharmaceuticals is more favorable than ABIVAX Société Anonyme.
Summary
ABIVAX Société Anonyme beats Zentalis Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
Get ABIVAX Société Anonyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABIVAX Société Anonyme Competitors List
Related Companies and Tools
